Welcome to our dedicated page for UBS ETRACS Alerian MLP Index ETN Series B SEC filings (Ticker: AMUB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AMUB filings document UBS AG’s role as the foreign private issuer behind the ETRACS Alerian MLP Index ETN Series B and the broader debt-securities platform under which UBS offers registered securities. UBS AG’s Form 6-K materials include quarterly and annual reporting references, IFRS financial information, capitalization tables, debt issued, registration-statement updates, legal opinions and offering-related disclosures.
The filing record also covers UBS Group and UBS AG risk and capital management, Pillar 3 regulatory capital metrics, leverage, liquidity and funding, governance signatures, and material reports involving debt securities. These disclosures frame AMUB as a senior unsecured UBS AG obligation whose value and payments depend on the note terms and UBS AG credit risk.
UBS AG filed a preliminary 424(b)(2) pricing supplement for a primary offering of Trigger Autocallable Contingent Yield Notes linked to the common stock of DexCom, Inc. The Notes pay a contingent coupon only when the underlying closes at or above a coupon barrier on an observation date and may be automatically called if the underlying closes at or above the initial level on an observation date before maturity.
If not called, and the final level is at or above the downside threshold on the final valuation date, investors receive the principal back; if below, repayment is reduced one-for-one with the underlying’s decline, and losses could reach 100% of principal. All payments are subject to UBS’s credit.
Key dates include trade date October 14, 2025, settlement October 16, 2025, final valuation October 12, 2028, and maturity October 16, 2028. The Notes are offered in $10 denominations with a minimum investment of 100 Notes. The estimated initial value is expected to be between $9.48 and $9.73 per $10 Note. The Notes will not be listed, and initial settlement is T+2 while secondary trades generally settle T+1.
UBS AG is offering $15,041,000 of Capped Market‑Linked Notes tied to the least performing of the Dow Jones Industrial Average and the S&P 500 Index, due April 15, 2027.
At maturity, if the least performing index shows a positive return, the payout equals principal plus that return capped at a maximum gain of 11.20% (maximum payment $1,112 per $1,000 note). If the least performing return is zero or negative, repayment is principal only. The Notes pay no interest and are subject to UBS credit risk.
Key terms include an estimated initial value of $997.10 per note, an issue price of $1,000, and an underwriting discount of $1.50 per note (proceeds to UBS $998.50 per note). Trade date is October 10, 2025; final valuation April 12, 2027. The Notes will not be listed on any exchange.